

**FLAVOXATE HYDROCHLORIDE- flavoxate hydrochloride tablet, film coated**  
**TAGI Pharma, Inc.**


-----  
**Flavoxate Hydrochloride Tablets, 100 mg**  
**Film-Coated**

**Rx Only**

**DESCRIPTION**

Flavoxate hydrochloride tablets contain flavoxate hydrochloride, a synthetic urinary tract spasmolytic.

Chemically, flavoxate hydrochloride is 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride. The empirical formula of flavoxate hydrochloride is  $C_{24}H_{25}NO_4 \cdot HCl$ . The molecular weight is 427.94. The structural formula appears below.



Each tablet for oral administration contains 100 mg flavoxate hydrochloride. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, dibasic calcium phosphate dihydrate, magnesium stearate, hypromellose, polydextrose, polyethylene glycol, titanium dioxide and triacetin.

**CLINICAL PHARMACOLOGY**

Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle.

In a single study of 11 normal male subjects, the time to onset of action was 55 minutes. The peak effect was observed at 112 minutes. 57% of the flavoxate hydrochloride was excreted in the urine within 24 hours.

**INDICATIONS AND USAGE**

Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/ urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections.

**CONTRAINDICATIONS**

Flavoxate hydrochloride is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

## WARNINGS

Flavoxate hydrochloride should be given cautiously in patients with suspected glaucoma.

## PRECAUTIONS

### Information for Patients

Patients should be informed that if drowsiness and blurred vision occur, they should not operate a motor vehicle or machinery or participate in activities where alertness is required.

### Carcinogenesis, Mutagenesis, Impairment of Fertility

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of flavoxate hydrochloride have not been performed.

### Pregnancy

Teratogenic Effects

#### *Pregnancy Category B*

Reproduction studies have been performed in rats and rabbits at doses up to 34 times the human dose and revealed no evidence of impaired fertility or harm to the fetus due to flavoxate hydrochloride. There are, however, no well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

### Nursing Mother

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when flavoxate hydrochloride is administered to a nursing woman.

### Pediatric Use

Safety and effectiveness in children below the age of 12 years have not been established.

## ADVERSE REACTIONS

The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.

**Gastrointestinal:** Nausea, vomiting, dry mouth.

**CNS:** Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.

**Hematologic:** Leukopenia (one case which was reversible upon discontinuation of the drug).

**Cardiovascular:** Tachycardia and palpitation.

**Allergic:** Urticaria and other dermatoses, eosinophilia and hyperpyrexia.

**Ophthalmic:** Increased ocular tension, blurred vision, disturbance in eye accommodation.

**Renal:** Dysuria.

## OVERDOSAGE

The oral LD<sub>50</sub> for flavoxate hydrochloride in rats is 4273 mg/kg. The oral LD<sub>50</sub> for flavoxate hydrochloride in mice is 1837 mg/kg.

It is not known whether flavoxate hydrochloride is dialyzable.

## **DOSAGE AND ADMINISTRATION**

### **Adults and children over 12 years of age**

One or two 100 mg tablets 3 or 4 times a day. With improvement of symptoms, the dose may be reduced. This drug cannot be recommended for infants and children under 12 years of age because safety and efficacy have not been demonstrated in this age group.

## **HOW SUPPLIED**

Flavoxate hydrochloride 100 mg tablets are available as white, round biconvex, film-coated tablets, debossed "58" on one side and plain on the other side, and are available in bottles of 100 and 1000.

Store at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container.

Distributed by:

TAGI Pharma

South Beloit, IL 61080

Manufactured by

Epic Pharma, LLC

Laurelton, NY 11413

### **Made in USA**

Revised 02/15

MF058REV02/15

OE1252

## **PRINCIPAL DISPLAY PANEL - 100 mg Tablets Bottle Label**

NDC 51224-154-50

**Flavoxate**

**Hydrochloride**

**Tablets**

**100 mg**

**Rx Only**

100 Film-Coated  
Tablets

tagiPHARMA

Exp. Date:

Lot No.:

**USUAL DOSAGE:** See accompanying literature for complete prescribing information.

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required.

Issued 02/11

LE1994

NDC 51224-154-50

# Flavoxate Hydrochloride Tablets

**100 mg**

**Rx Only**

100 Film-Coated Tablets



Each film-coated tablet contains:  
Flavoxate Hydrochloride.....100 mg

KEEP TIGHTLY CLOSED.

**KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.**

Manufactured by:  
Epic Pharma, LLC  
Laurelton, NY 11413

**Made in USA**

Distributed by:  
TAGI Pharma  
South Beloit, IL 61080



## FLAVOXATE HYDROCHLORIDE

flavoxate hydrochloride tablet, film coated

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:51224-154
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
Flavoxate hydrochloride (UNII: 9C05J6089W) (Flavoxate - UNII:3E74Y80MEY)	Flavoxate hydrochloride	100 mg

### Inactive Ingredients

Ingredient Name	Strength
silicon dioxide (UNII: ETJ7Z6XBU4)	
starch, corn (UNII: O8232NY3SJ)	
dibasic calcium phosphate dihydrate (UNII: O7TSZ97GEP)	
magnesium stearate (UNII: 70097M6I30)	
Hypromellose, Unspecified (UNII: 3NXW29V3WO)	
polydextrose (UNII: VH2XOU12IE)	
titanium dioxide (UNII: 15FIX9V2JP)	
triacetin (UNII: XHX3C3X673)	
propylene glycol (UNII: 6DC9Q167V3)	

### Product Characteristics

<b>Color</b>	WHITE	<b>Score</b>	no score
<b>Shape</b>	ROUND	<b>Size</b>	11mm
<b>Flavor</b>		<b>Imprint Code</b>	58
<b>Contains</b>			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51224-154-50	100 in 1 BOTTLE; Type 0: Not a Combination Product	03/25/2011	
2	NDC:51224-154-70	1000 in 1 BOTTLE; Type 0: Not a Combination Product	03/25/2011	

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA076835	03/25/2011	

**Labeler** - TAGI Pharma, Inc. (963322560)

Revised: 11/2017

TAGI Pharma, Inc.